OCA
AMAM

Octagon Capital Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

Octagon Capital Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-122,800
Closed -$325K – 39
2022
Q2 		$325K Sell
122,800
-26,600
-18% -$101K 0.09% 20
2022
Q1 		$616K Sell
149,400
-187,468
-56% -$959K 0.13% 24
2021
Q4 		$3.04M Sell
336,868
-13,132
-4% -$147K 0.59% 23
2021
Q3 		$4.72M Sell
350,000
-100,000
-22% -$1.8M 1.16% 20
2021
Q2 		$8.82M Buy
+450,000
New +$7.67M 1.83% 17

Other funds holding AMAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Octagon Capital Advisors's AMAM Position: Q3 2022 in Review

Octagon Capital Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q3 2022, closing a stake of 122,800 shares — an estimated $325K sold.

Octagon Capital Advisors first reported a position in AMAM in Q2 2021 and held it in 5 quarters. The position peaked at $8.82M in Q2 2021. 16 funds tracked by Wall St. Rank hold AMAM as of Q3 2022.

  • Octagon Capital Advisors reported no remaining Ambrx Biopharma Inc position as of Q3 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 122,800 Ambrx Biopharma Inc shares in Q3 2022, an estimated $325K.
  • Octagon Capital Advisors first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 5 quarters.
  • Octagon Capital Advisors's Ambrx Biopharma Inc position peaked at $8.82M in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2022.

Based on Octagon Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.